Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EG-70 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| EG-70 (phase 1) | DRUG | Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen. |
| EG-70 (phase 2) | DRUG | Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle. |
EG-70 is an investigational small molecule being developed for the treatment of superficial bladder cancer, specifically non-muscle invasive bladder cancer with carcinoma in situ. It is being studied in patients who are BCG-unresponsive, have high-risk NMIBC incompletely treated with BCG, or are BCG-naïve.
EG-70 is being developed by enGene Holdings Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ENGN. The company is conducting clinical trials to evaluate the safety and efficacy of EG-70 in patients with superficial bladder cancer.
EG-70 is currently in Phase 2 clinical development. It is being studied in the LEGEND trial, which is a Phase 1/Phase 2 study. The drug is investigational and has not been approved by regulatory authorities, as it is still undergoing clinical evaluation.
EG-70 is being evaluated in the LEGEND Study (NCT04752722), a Phase 1/Phase 2 trial with an enrollment of 350 participants. The study is recruiting patients with superficial bladder cancer, including non-muscle invasive bladder cancer with carcinoma in situ, and is currently active.
EG-70 is the primary name for this investigational drug candidate. No alternative names have been established for EG-70 in the available clinical trial information. It is being studied under this name in the LEGEND trial for the treatment of superficial bladder cancer.